Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUDCA in Ulcerative Colitis
NCT04114292Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tauroursodeoxycholic acid in ulcerative colitis (UC), sponsored by Washington University School of Medicine. Primary endpoint: Effect of TUDCA treatment on ER stress in colon biopsy tissues at 6 weeks. Started Jan 2019; status: completed.
02
Drugs
tauroursodeoxycholic acid
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04114292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04114292.